Login / Signup
Michael B Ward
(Michael Ward)
ORCID
Publication Activity (10 Years)
Years Active: 2020-2023
Publications (10 Years): 6
Top Topics
Adverse Drug
Stem Cell Transplantation
Hydrogen Peroxide
Chronic Obstructive Pulmonary Disease
Top Venues
Drug safety
British journal of clinical pharmacology
Journal of clinical pharmacy and therapeutics
Respiratory research
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Jack L Janetzki
,
Nicole L Pratt
,
Michael B Ward
,
Matthew J Sykes
Application of an Integrative Drug Safety Model for Detection of Adverse Drug Events Associated With Inhibition of Glutathione Peroxidase 1 in Chronic Obstructive Pulmonary Disease.
Pharmaceutical research
(2023)
Jack L Janetzki
,
Matthew J Sykes
,
Michael B Ward
,
Nicole L Pratt
Chronic Obstructive Pulmonary Disease Adverse Event Signals Associated with Potential Inhibitors of Glutathione Peroxidase 1: A Sequence Symmetry Analysis.
Drug safety
(2023)
Thu-Lan Kelly
,
Michael B Ward
,
Nicole L Pratt
,
Emmae Ramsay
,
Marianne H Gillam
,
Elizabeth Ellen Roughead
The association between exacerbation of chronic obstructive pulmonary disease and timing of paracetamol use: a cohort study in elderly Australians.
Respiratory research
23 (1) (2022)
Jack L Janetzki
,
Matthew J Sykes
,
Michael B Ward
,
Nicole L Pratt
Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease-A sequence symmetry analysis approach.
Journal of clinical pharmacy and therapeutics
46 (6) (2021)
Stephanie E Reuter
,
Hayley B Schultz
,
Michael B Ward
,
Crystal L Grant
,
Gemma M Paech
,
Siobhan Banks
,
Allan M Evans
The effect of high-dose, short-term caffeine intake on the renal clearance of calcium, sodium and creatinine in healthy adults.
British journal of clinical pharmacology
87 (11) (2021)
Courtney De Vries
,
Svetla Gadzhanova
,
Matthew J Sykes
,
Michael B Ward
,
Elizabeth Ellen Roughead
A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants.
Drug safety
44 (3) (2020)